Refine by
Clinical Success Articles & Analysis
45 articles found
Such therapies have shown promise in clinical trials, particularly in oncology, where tumors may express multiple surface antigens. ...
By providing a platform that accurately reflects human biology, organ-on-a-chip systems allow for the identification of adverse drug reactions early in the discovery process, thereby increasing the likelihood of success in clinical trials. Furthermore, advancements in genomics and proteomics have paved the way for the creation of more refined disease models. ...
This not only accelerates the identification of promising therapeutic candidates but also enhances the likelihood of successful translation into clinical practice. Furthermore, understanding the tumor microenvironment through these models can lead to the discovery of novel biomarkers, facilitating patient stratification and improving treatment decisions. ...
Medical advancement relies on clinical trials, which are essential for the development of safe and effective innovative treatments. However, the success and general applicability of these treatments heavily depend on the diversity of the participants ...
This not only expedites the development of novel therapeutics but also improves the success rate of clinical trials, ultimately benefiting patients in need of innovative treatments. ...
This not only expedites the development of novel therapeutics but also improves the success rate of clinical trials, ultimately benefiting patients in need of innovative treatments. ...
This strategy had its earliest clinical success with Mylotarg and was later used in Besponsa. However, the stability of the acid-cleavable linker severely limits its application in ADCs. ...
This strategy achieved the earliest clinical success with Pfizer's Mylotarg® (AcBut Linker). Although reducible disulfides are also employed, linker contains an acid-sensitive N-acylhydrazone linkage. ...
Before a new drug candidate can progress to clinical trials and ultimately reach the market, it needs to undergo rigorous testing in various model systems to assess its efficacy and safety. ...
The AI predicts peptides from in vitro to clinical efficacy with an 80% success rate. The development of an ingredient goes through three phases, from discovery to preclinical biology testing and clinical trials. PeptiYouth delivers clinically proven efficacy on five critical signs of aging, making it a valuable addition to any ...
Through its bioactive peptide finder, Magnifier NπΦ, the company can boast a clinical trial success rate of 80%. Development of an ingredient goes through three phases, from discovery to preclinical biology testing and clinical trials. ...
As part of our quick fire questions series – or QFQs – we spoke to Dr. Andy Franklyn-Miller, Chief Medical and Innovation Officer at Nuritas about intelligent ingredients, explaining peptides and proving an AI model in life science. There is a lack of innovation within ingredients in food, many have been discovered decades ago, mostly with cost, taste and texture in mind. However as ...
Cardiovascular safety liabilities caused 52.3 % of 44 marketed data from 1980 to 2011, and cardiovascular disease remains the leading cause of death globally, yet only 8.7% of cardiovascular drugs successfully pass clinical trials. These statistics demonstrate the need to address a patient’s specific genetic make-up and phenotype by adopting a personalized treatment ...
Drugs such as the anti PD-1 antibody bind immune checkpoint molecules on T cells, so that cancer cells cannot bind them to inhibit T cell function. These drugs have shown some success; the caveat is that while immune cell function is no longer hampered with regards to cancer cells, it is not targeted to tumor-specific T cells. ...
The ability to fabricate complex 3D structures containing live cells for drug discovery and tissue engineering has huge potential. To realise successful clinical translation, biologistics need to be considered. Refinements in the storage and transportation process from sites of manufacture to the clinic will enhance the success ...
Accuracy in medical coding is a vital aspect in aiding clinical trial operation success. It has presented an excellent opportunity for medical coders, working hand-in-hand with AI-enhanced computer-assisted coding systems, to quickly identify and validate the correct codes. ...
ByClinion
For example, the drug developer has initiated four new clinical trials in 2022 alone. It's also a promising sign of strength for investors, although long-term performance will be driven by execution and clinical trial data. ...
The Clinical CRISPR Successes Are Stacking Up. But Where’s the Emphasis on Quality Control? ...
The Holiday season often brings mixed feelings for many. While it can be a time of relaxation with friends and family for some, for others, preparing for this time means ensuring business continuity despite a typical slow down. This can be a source of undue stress if it is not suitably planned for. ...
” And, although this has not yet been studied in clinical trials, other vessel preparation techniques, such as debulking with atherectomy, could also be employed pre-procedure in highly calcified vessels, he says. ...